Cerebral sinovenous thrombosis during asparaginase treatment. Case 3.
A boy (age: 7 1/2 years) with acute lymphoblastic leukaemia developed thrombosis of the sinus sagitalis superior with secondary haemorrhagic infarction while on induction treatment with vincristine, prednisone, and asparaginase. Based on this report, the potential pathogenic mechanisms are discussed with respect to congenital prothrombotic defects as well as to the role of antileukaemic treatment. Current hypotheses on mechanisms for thromboembolism in children and proposed prophylactic strategies are briefly summarized.
Leibundgut
K
K
Universitäts-Kinderklinik, Pädiatrische Hämatologie/Onkologie, Inselspital, 3010 Bern, Switzerland. kurt.leibundgut@insel.ch
Hirt
A
A
Zwicky
C
C
Wuillemin
W A
WA
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000235:genetics; D002648:Child; D050676:Core Binding Factor Alpha 2 Subunit; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D020767:Intracranial Thrombosis / Q000139:chemically induced*; D008279:Magnetic Resonance Imaging; D008297:Male; D018919:Neovascularization, Physiologic; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D013997:Time Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome; D000097764:ETS Translocation Variant 6 Protein
D000970:Antineoplastic Agents; D001215:Asparaginase; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein